CovidResearchTrials by Shray Alag

CovidResearchTrials Covid 19 Research using Clinical Trials (Home Page)

convalescent plasma from recovered COVID 19 donorWiki

Developed by Shray Alag
Clinical Trial MeSH HPO Drug Gene SNP Protein Mutation

Correlated Drug Terms (1)

Name (Synonyms) Correlation
drug2811 epidemiological and demographic characteristics Wiki 1.00

Correlated MeSH Terms (3)

Name (Synonyms) Correlation
D011014 Pneumonia NIH 0.06
D045169 Severe Acute Respiratory Syndrome NIH 0.05
D018352 Coronavirus Infections NIH 0.04

Correlated HPO Terms (1)

Name (Synonyms) Correlation
HP:0002090 Pneumonia HPO 0.06

There is one clinical trial.

Clinical Trials

1 A National Collaborative Multicenter Phase II Study for Potential Efficacy of Convalescent Plasma to Treat Severe COVID-19 and Patients at High Risk of Developing Severe COVID-19

Coronavirus disease (COVID-19) pandemic has started to affect Saudi Arabia and is expected to cause a lot of morbidities and many patients, especially the elderly, will require intensive care unit (ICU) support to survive as its lethality increases with the increasing age. Development of a vaccine by pharmaceutical companies like Roche and antibody concentrates from convalescent patients' plasma by Takeda will take 10-12 months to complete, and we speculate that it will be overwhelmingly expensive and limited in supply. We are presenting this urgent proposal to use the convalescent plasma to save the lives of severely affected COVID-19 patients. Most of the logistic support is already available in MOH Saudi Arabia, and it will be a cheap and quick technique based on the time-tested principles of passive immunization which is supported by the most recent data from China. We are proposing to test the therapeutic potential of convalescent plasma (from patients who have fully recovered from COVID-19) in treating patients with serious COVID-19 disease or those who are at risk of developing a serious disease based on their comorbidities profile. Convalescent plasma could provide our first-line defense for people with Covid-19, especially those who are older and at a much higher risk for complications. Amid the COVID-19 pandemic, with no available vaccine or proven antiviral drug, antibodies from recovering patients could provide a "stopgap" measure to help in controlling the pandemic effects on health and economy. We plan to recruit at least 40 consenting donors and patients. Non-consenting patients will serve as controls.

NCT04347681 Convalescent Plasma for COVID 19 Other: convalescent plasma from recovered COVID 19 donor

Primary Outcomes

Description: number of days in ICU

Measure: ICU length of stay

Time: Time from transfer into ICU to time of transfer out from ICU, Up to 12 weeks.

Description: reporting adverse events associated with transfusion as per transfusion medicine guidelines.

Measure: Safety of convalescent plasma & Serious adverse reactions.

Time: time from signing consent to one month after transfusion, Up to 12 weeks.

Secondary Outcomes

Description: number of days patient spend on ventilator.

Measure: Number of days on mechanical ventilation

Time: Time from intubation to time of extubation, Up to 12 weeks.

Description: the death rate in 30 days after signing consent

Measure: 30 days of mortality

Time: 30 days from signing consent Up to 12 weeks.

Description: number of days to symptoms resolution and COVID 19 negative PCR ( by NP swap)

Measure: Days to clinical recovery .

Time: time from signing consent to recovery,Up to 12 weeks.

No related HPO nodes (Using clinical trials)